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Objectives: To investigate whether women with overactive bladder (OAB) symptoms and
no evidence of clinical infection by conventional clean-catch midstream urine cultures have
alternative indicators of sub-clinical infection.
Patients/Subjects, Materials & Methods: The study was a prospective, blinded case-
control study with 147 participants recruited, including 73 OAB patients and 74 controls.
The OAB group comprised female patients of at least 18 years of age who presented with
OAB symptoms for more than 3 months. Clean-catch midstream urine samples were
examined for pyuria by microscopy; subjected to routine and enhanced microbiological
cultures and examined for the presence of 10 different cytokines, chemokines, and
prostaglandins by ELISA.
Results: The mean age and BMI of participants in both groups were similar. No
significant difference in the number of women with pyuria was observed between
OAB and control groups (p = 0.651). Routine laboratory cultures were positive in
three (4%) of women in the OAB group, whereas the enhanced cultures isolated bacteria
in 17 (23.2%) of the OAB patients. In the control group, no positive cultures were
observed using routine laboratory cultures, whereas enhanced culture isolated bacteria
in 8 (10.8%) patients. No significant differences were observed in the concentrations of
PGE2, PGF2a, MCP-1, sCD40L, MIP-1b, IL12p70/p40, IL12/IL-23p40, IL-5, EGF and
GRO-a between the OAB and control groups.
Conclusions: Patients with OAB symptoms have significant bacterial growth on
enhanced culture of the urine, which is often not detectable through routine culture,
suggesting a subclinical infection. Enhanced culture techniques should therefore be used
routinely for the effective diagnosis and management of OAB.
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Urinary incontinence (UI) is prevalent in society, affecting
women of all ages and with potential to seriously impact the
physical, psychological, and social wellbeing of affected
individuals. According to the International Continence Society
(ICS), overactive bladder (OAB) syndrome is characterized by
urinary urgency usually accompanied by frequency and nocturia,
with or without urgency urinary incontinence, and in the
absence of urinary tract infection or other obvious pathology
(Abrams et al., 2003; Haylen et al., 2010). As a major cause of
urinary incontinence, OAB affects 12.8% of women over the age
of 18 years of age and the incidence rises with age (Irwin et al.,
2006). The incidence of any OAB symptom is as high as 48% (de
Boer et al., 2011), however, there is a paucity of evidence
associating OAB symptoms with urinary infection. OAB
patients that are refractory to treatment are a particular
challenge with the lack of a treatment response often attributed
to an undiagnosed infection, despite this having been ruled out
by urinalysis and standard culture, or poor drug efficacy.
The impact of OAB on quality of life can be significant. With
adverse effects ranging from poor sleep quality to impaired
emotional well-being to social disruption and difficulties in
education and employment, several studies have highlighted
the negative impact that this syndrome can have on patients’
lives (Stewart et al., 2003; Bartoli et al., 2010). Added to this are
significant healthcare costs associated with disease management,
which although difficult to accurately determine, are estimated to
be around €5bn for major economies across Europe and up to
$82bn in the United States (Reeves et al., 2006; Reynolds
et al., 2016).
Despite the option for non-pharmacological interventions,
such as lifestyle changes, behavioral therapy, and pelvic floor
muscle training; most women with OAB will need drug
treatment, which can include antimuscarinic drugs,
anticholinergics, beta 3-receptor antagonists or botulinum
toxins (Andersson et al., 1999; NICE, 2016a). In cases where
drug therapy fails, additional management strategies including
percutaneous posterial tibial nerve stimulation or sacral nerve
stimulation, augmentation cytoplasty or urinary diversion can be
considered. Although these are only indicated following
extensive multidisciplinary team review and the failure of other
treatment options (NICE, 2016b).
A key facet of the diagnosis of OAB is the absence of urinary
tract infection (UTI), which is defined by urinary pathogens
within a clean-catch midstream urine (MSU) sample and the
presence of clinical symptoms. Although OAB and UTI share
similar symptoms such as urgency frequency and nocturia, the
onset of symptoms is different; UTI exhibiting acute symptoms
and OAB exhibiting chronic symptoms. The similarity of sensory
bladder symptoms associated with OAB and UTI can complicate
disease management if UTI is not first excluded. Although there is
no officially accepted standard for the minimum level of bacteria
in a MSU specimen defining an infection, many laboratories use
105 colony forming units (CFU)/mL urine as the UTI threshold
(Kass, 1957), whilst others have proposed a threshold of ≥102Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2CFU/ml in symptomatic women presenting with dysuria and
cystitis-like symptoms (Stamm, 1983). Conventional MSU
culture judged positive at ≥105 CFU/ml can fail to detect 50% of
all clinically significant, symptomatic urinary infections in OAB
patients (Khasriya et al., 2008). As symptoms of OAB and cystitis
overlap, a negative MSU is not entirely reliable.
The aim of the present study was to investigate whether urine
from women with OAB symptoms (and no evidence of clinical
infection by conventional MSU) have significant markers of sub-
clinical infection when compared to individuals with no
OAB symptoms.PATIENTS/SUBJECTS, MATERIALS
AND METHODS
The study was a prospective, blinded case control study approved
by the Southwest Wales Research Ethics Committee (REC
reference number 12/WA/0405), performed at Singleton
Hospital, Swansea, and Swansea University Medical School
from 2012 to 2015. The objectives of the study were to
discover whether patients with OAB exhibit significant pyuria
on fresh microscopy, harbor bacteria undetected by routine MSU
cultures, and if so, to identify and quantify such bacteria. In
parallel, we determined whether these patients displayed elevated
levels of inflammatory markers.
147 subjects were recruited: 73 OAB patients and 74 controls.
Inclusion criteria were female patients of at least 18 years of age
presenting with OAB symptoms for more than 3 months.
Symptoms were defined as greater than 1 episode/week of an
uncontrolled urge to void causing incontinence. Exclusion
criteria included hematuria, obstructive uropathy, vaginitis,
urothelial carcinoma, urinary tract infection, pelvic radiation
disease, neurogenic bladder, women with predominant stress
urinary incontinence, liver disease, patients receiving antibiotics,
an inability to give consent and understand English, and
participation in other studies where the intervention is likely to
affect their condition. The control group was recruited on a
voluntary basis and comprised women aged at least 18 years of
age, with no history of urinary infection, OAB symptoms or
urge incontinence.
All participants completed a study specific Proforma and
International Consultation on Incontinence Questionnaire-
Overactive Bladder (ICIQ-OAB) (Avery et al., 2004).
Information was obtained on patient’s age, BMI, past medical
history, co-morbid conditions, urinary symptoms, prolapse
symptoms and medication history. The ICIQ-OAB is a
validated questionnaire (https://www.baus.org.uk/_userfiles/
pages/files/Patients/Leaflets/ICIQ-OAB.pdf) used to screen for
overactive bladder. It comprises 4 questions pertaining to
frequency of micturition, nocturia, urgency and urge urinary
incontinence. Each question is scored from 0 to 4 depending on
the presence and severity of symptoms. The overall score of the
ICIQ-OAB questionnaire ranges from 0-16 with greater values
indicating increased symptom severity.September 2021 | Volume 11 | Article 752275
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Participants provided an MSU specimen that was immediately
divided into four equal aliquots. Aliquot one was analyzed
directly for pyuria (white cell count ≥103 CFU/ml) using
microscopy within one hour of collection in a KOVA slide
hemocytometer (Perera, 1985; Emerson and Emerson, 2005).
Enhanced culture was carried out by inoculating 0.001 ml of
urine onto chromogenic (trypticase soy agar with 5% sheep
blood), chocolate, and fastidious anaerobic agar (FAA) culture
plates within one hour of sample collection. The chromogenic
and chocolate agar plates were incubated aerobically for 5 days at
35-37°C. The anaerobic plate was incubated anaerobically at
35°C for 5 days. Cultures were quantitated, and microorganisms
isolated in the range of ≥103 CFU/ml were identified. Bacterial
colonies were identified by color change and size, and
identification subsequently confirmed by matrix assisted laser
desorption ionization-time offlight mass spectrometry (MALDI-
TOF MS). Identification of microbes by MALDI-TOF MS was
achieved either by comparing the peptide mass fingerprint
(PMF) of the organisms with the PMFs contained in a
database, or by matching the masses of biomarkers of
organisms with a proteome database (Singhal et al., 2015).
MSU samples containing one or two known uropathogens at
≥103 CFU/ml were reported as enhanced culture positive.
Specimens containing three or more isolates were reported
as contaminated.
Aliquot 2 was transferred to a sterile MSU boric acid bottle
and analyzed using an automated urine microscopy analyzer
(IRIS 2000, Beckman Coulter, High Wycombe, UK) (Ben-Ezra
et al., 1998; Ottiger & Huber, 2003). Particle counts were
measured per unit of volume based on image number and
volume scanned, and positive samples (single microbial species
at a density of ≥105 CFU/mL) were cultured, either fresh or after
overnight storage at 4°C on chromogenic plates for 24 h at 35°C.
The presence of multiple growths or micro-organisms <105
CFU/mL are suggestive of urethral or vaginal contamination
and are either reported as mixed growth or negative culture.
Aliquot 3 was snap-frozen and stored at -80°C prior to
determining the levels of Prostaglandin E2 (PGE2, Abnova,
Taiwan), Prostaglandin F2 alpha (PGF2 a, Abnova), Monocyte
Chemotactic Protein-1 (MCP-1, R&D Systems, UK), Soluble
fraction of the CD40 Ligand (sCD40L, R&D Systems),
Macrophage inflammatory protein-1b (MIP-1b, R&D Systems),
Interleukin 12p70/p40, IL-12p70/p40, R&D Systems), Interleukin
5 (IL-5, R&D Systems), Epidermal Growth Factor (EGF, R&D
Systems), and Growth-Related Oncogene-alpha (GROa,
RayBiotech, USA) using commercially available Enzyme-Linked
Immunosorbent Assay (ELISA) kits.
Aliquot 4 was stored in Singleton hospital microbiology
laboratory for a five-year period with ethical approval for
storage and future sample testing.
Sample Size Calculation and
Statistical Analysis
Sample size was calculated using results from a comparative
study (Tyagi et al., 2010), and from a pilot study conducted byFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3this group. A sample of 36 per group was necessary to ensure 5%
significance at a power of 80%. The precautionary step of
allowing for a 10% shortfall in recruitment and 10% missing
data resulted in a minimum total sample size of 45. Statistical
analyses were performed using the IBM SPSS version 20.0
software (IBM Corp, NY, USA). Parametric statistical tests
were used wherever possible, but due consideration was given
to the distributional requirements of these tests, and suitable
alternatives used where necessary. We used the Mann–Whitney
test for comparison between groups for interval scale data.
Chi-squared and McNemar’s tests were used for analysis of
nominal data. A p-value ≤ 0.05 was considered to indicate
statistical significance.RESULTS
Demographics
A total of 74 controls and 73 OAB patients were included in the
study. The two groups were matched for age and BMI. The
mean age and BMI of participants in the control group was 53
years (range 38-77) and 26 kg/m2 (range 20-50) compared to
57 years (range 33-74) and 27 kg/m2 (range 20-43),
respectively. The demographic and clinical data of both
groups is shown in Table 1. The OAB group had a higher
incidence of previous gynecological surgery, including stress
urinary incontinence (SUI) surgery. OAB patients also had a




The ICIQ-Questionnaire score analysis demonstrated significantly
higher scores in the OAB group compared to controls (Table 2, p
< 0.001), with the control subjects being completely asymptomatic
and receiving no treatment. Over 50% (40/73) of OAB patients
were undergoing interventions, including 10 (14%) undertaking
bladder retraining and pelvic floor muscle exercises, 23 (32%)
receiving anti-muscarinic therapy, 4 (5%) receiving a Beta-3
agonist, and 3 (4%) awaiting botulinum toxin bladder injections
having failed medical therapy.
Direct Microscopy Analysis for Pyuria
No significant differences between groups (16.4% OAB and
13.5% control, p = 0.65 and p = 0.44, respectively) were noted
in the number of pyuria positive (white cell count ≥103 CFU/ml)
samples, as determined by hemocytometry or IRIS 2000
microscopy. This suggests that while useful for most women
with high-count UTI, pyuria is a weak marker of low-grade
infections and its value in lower urinary tract symptom (LUTS)
patients, including OAB patients, is unclear.
Routine and Enhanced Urine Cultures
Positive samples, identified by IRIS 2000 microscopy analysis,
were cultured on chromogenic media plate at 37°C for 24 hours.
The 3 control samples, initially reported as positive, wereSeptember 2021 | Volume 11 | Article 752275
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range of 103-104 CFU/mL and one had mixed growth. For the 9
cultured OAB samples, 2 had mixed growth, 4 had growth in
range of 103 CFU/mL and were reported as negative, and 3 were
reported as positive with E. coli growth present at >105 CFU/ml.
Enhanced culture of all samples (73 OAB and 74 controls)
resulted in the isolation of a significantly higher number (p =
0.017) of uropathogens from 23 (31.5%) OAB samples and 11
(14.8%) control samples. After excluding mixed growth cultures,
17 (23.2%) OAB and 8 (10.8%) controls were found to have one
or two microorganisms present (Table 3), including E. coli,
Enterococcus faecalis, Morganella morganii, Proteus mirabilis,
coliform, Streptococcus, and Staphylococcus species (Table 4).
Enhanced culture identified additional microorganisms in 14
(82%) samples that tested negative using routine culturing
methods, with bacteria being isolated from the majority of
MSU specimens and highlighting the potential limitations of
routine methods for OAB screening. Samples were only reported
as positive when known uropathogens were present, however
interestingly, vaginal commensals including lactobacilli,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4corynebacteria, gardnerella, and alpha-hemolytic streptococci
species were more common in control samples than OAB
patient samples.
Analysis of Prostaglandins, Inflammatory
Chemokines, and Cytokines
An association between inflammatory biomarkers and OAB has
previously been suggested. To explore this, we investigated whether
levels of these markers were altered inMSU samples fromOAB and
control patients. No significant differences between the OAB and
control samples were noted for any of the markers evaluated (PGE2,
PGF2a, MCP-1, sCD40L, MIP-1b, IL-12p70, IL-12p40, IL-5, EGF,
and GROa, Table 5), the mean values of which were within the
normal physiological range for a healthy person.DISCUSSION
The significant impact of OAB on quality of life makes early
diagnosis and effective treatment essential. SymptomaticTABLE 1 | Demographic and clinical data in the OAB and control groups.
Control (n = 74) OAB (n = 73) p-value
Demographics Age Mean 53.9375 57.3889 0.117
BMI mean 26.7973 27.9701 0.980
SUI 15 (20%) 60 (82%) <0.001
Prolapse 6 (8%) 32 (44%) <0.001
Voiding dysfunction 30 (41%) 1 (1%) <0.001
Dysuria 7 (9%) 0 (0%) <0.001
Previous surgery All 10 (13.5%) 25 (34%) <0.001
TAH 6 (8.1%) 17 (23.3%) –
VH+- PFR 2 (2.7%) 3 (4.1%) –
PFR 3 (4.1%) 4 (5.5%) –
Manchester Repair 1 (1.4%) –
Previous incontinence surgery All 1 (1%) 5 (7%) 0.014
TVT=1 1 (1.4%) 2 (2.7%) –
TVT-O/TOT=2 2 (2.7%) –
Bladder sling 1(1.4%) –September 2021 | Volume 11 | ArticleBoth groups were comparable for age and BMI but had significant differences in the presence of SUI, prolapse symptoms, voiding dysfunction, dysuria, and previous surgery. SUI, Stress
urinary Incontinence; TAH, Total Abdominal Hysterectomy; VH± PFR, Vaginal hysterectomy ± Pelvic floor repair; PFR, Pelvic floor repair; TVT, Transvaginal tape; TVT-O, Transvaginal tape-
obturator; TOT, Trans-obturator tape.TABLE 2 | ICIQ OAB scores in Controls and OAB patients.
Overall score Control (n = 74) OAB (n = 73) p-value
Median OAB symptom score 0/16 0/16 1 8 <0.0001
Frequency 0/4 0 1 <0.0001
Nocturia 0/4 0 2 <0.0001
Urgency 0/4 0 2 <0.0001
Urge Incontinence 0/4 0 2 <0.0001TABLE 3 | Routine and enhanced culture results in controls and OAB groups.
Control (n = 74) OAB (n = 73) p-value
Routine Culture positive 0 (0%) 3 (4%) 0.079
Enhanced culture positive 11 (14.8%) 23 (31.5%) 0.017
Enhanced culture positive (excluding mixed growths) 8 (8.1%) 17 (23.2%) 0.045752275
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routine microbiological culture, complicates the diagnostic
process and means there is a need for more optimized
approaches. By exploiting enhanced culture techniques, we
have demonstrated a significantly higher rate of bacterial
infection in OAB (23.28%) patients compared to control
subjects (10.8%), than that estimated via the routine testing
typically used to exclude infection in urinary samples. Data that
are consistent with earlier reports (Khasriya et al., 2008; Khasriya
et al., 2009; Hilt et al., 2014). An increased prevalence, in the
control group, of vaginal commensal bacteria, which are
regarded as an important component of the vaginal mucosa
defence against genital infections, was also noted. By acidifying
the vaginal microenvironment, these bacteria inhibit the
colonization of invading pathogens through competitive
exclusion. Our data are consistent with such a role for
commensal bacteria in providing genital track mucosa
homeostasis in healthy women, and with the clinical picture
(Thomas-White et al., 2018). Using routine culture methods,
only 4% of OAB samples in the present study were positive for
uropathogens, demonstrating its limitations, and the incidence
of pyuria was similar between OAB patients and control subjects.
Despite a lack of consistency in the literature regarding the role
of pyuria as diagnostic in LUTS patients, with different studies
recording white cell counts ranging from 58%-74% in patients
with OAB (Malone-Lee et al., 2007) to 22%-42% in LUTSFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5patients (Kim et al., 2006), pyuria is generally considered a
weak marker of low-grade infections, which is consistent with
our data.
In contrast to some other studies, and despite the detection of
uropathogens by enhanced culture techniques. We did not find
any significant increase in the inflammatory markers tested in
this study, suggesting that the sub-clinical levels of bacteria
detected had not triggered an inflammatory response. The
presence of cytokines in the urine has been studied in various
bladder and kidney disorders as it provides a non-invasive tool
for inflammation (Ninan et al., 1999; Abdel-Mageed et al., 2003).
However, there is inconsistency in the studies analyzing the role
of inflammatory markers in OAB. Tyagi et al. analyzed the urine
of 17 idiopathic OAB patients and eight asymptomatic controls
for 12 different chemokines, cytokines, and growth factors in a
prospective study finding elevated levels of nine of these markers
in the urine of OAB patients (Tyagi et al., 2010). The small
sample size, cross-sectional study design, lack of comorbidities
matching, and age disparity between the OAB and control group,
is a potential limitation of Tyagi’s study, however. Ghoniem et al.
analyzed an array of cytokines in the urine of 20 OAB patients, 20
controls, and 16 patients with UTI in a prospective, single blind
study. Consistent with our observations, most of the cytokines
were not elevated in the urine of OAB patients compared to
controls or UTI patients. In fact, certain cytokines were
significantly downregulated in OAB (Ghoniem et al., 2011).TABLE 4 | Types of microorganisms cultured in both groups.
Group Microorganism cultured Number
OAB (n = 17) 107-108 Escherichia coli 4
107-108 Enterococcus faecalis 2
106 coliform 2
106-107 Enterococcus faecalis + 106-107 Streptococcus agalactiae 1
108 E. coli +106-107 Streptococcus 2
106-107 Morganella morganii +107-108 Streptococci 2
106 coliform + 107Streptococcus pneumoniae 2
106 coliform +106-107 Staphylococcus 2
Control (n = 8) 106 Enterococcus faecalis 1
108 Enterococcus faecalis + 106-107 E. coli 1
106-107 Proteus mirabilis 1
107-108 Escherichia coli + 107-108 Streptococcus anginosus 1
107-108 coli + 106-107 Staphylococcus haemolyticus 1
107-108 Enterococcus faecalis + 107-108 Staph 1
106 coliform + 106 Streptococcus anginosus 2September 2021 | Volume 11 | ArticlTABLE 5 | Concentrations (pg/ml) of inflammatory prostaglandins, chemokines, and cytokines in OAB patients and controls.
OAB Control p-value
Mean ± SD (pg/ml) Mean ± SD (pg/ml)
EGF 10352.26 ± 9967.72 11424.62 ± 11895.60 0.860
MCP 95.77 ± 531.20 95.79 ± 558.46 0.519
CD40 972.03 ± 515.95 1140.86 ± 948.71 0.938
PG E2 102.27 ± 61.46 124.06 ± 93.83 0.336
PG F2A with dilution 9963.58 ± 5491.48 12300.75 ± 6176.91 0.081
IL-5 0.74 ± 0.93 0.84 ± 0.67 0.247
IL12 p70 1.65 ± 2.28 1.04 ± 1.32 0.213
GRO-alpha 2.01 ± 3.12 1.40 ± 3.25 0.089
MIP-1 B 1.71 ± 1.91 3.31 ± 3.66 0.078
IL12P40 11.36 ± 11.49 10.38 ± 12.13 0.408e 752275
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to be established, and their utility as biomarkers for OAB
diagnosis does not appear useful.
Heterogeneous results are also apparent for urine
prostaglandins. Significant elevation in PGE2 and PGF2a in
OAB patients compared to controls has been reported by Kim
et al. and Kang Jun Cho, although prostaglandin concentrations
were not corrected for urine creatinine concentration (Kim et al.,
2006; Cho et al., 2013). Corroborating our study, however, Hsin-
Tzu Liu did not demonstrate any significant difference in urinary
PGE2/Cr levels among patients with interstitial cystitis/bladder
pain syndrome (IC/BPS), OAB or controls (Liu et al., 2010).
Thus, the role of urinary prostaglandins in the diagnosis of OAB
also appears limited. Whilst the literature supports a role for
inflammation in the pathophysiology of the overactive bladder,
with the presence of many inflammatory markers described in
OAB, studies performed with the purpose of identifying specific
inflammatory markers have not demonstrated consistency.
Together, our data and the observations of others (Khasriya
et al., 2008; Tyagi et al., 2010; Hilt et al., 2014), demonstrate that
bacterial infection cannot be reliably excluded by routine culture
and that inflammatory markers are an unreliable indicator of
infection. Enhanced techniques or other methods, such as the
identification of bacterial DNA in urine appear to be needed in
all patients presenting with symptoms of OAB. Approximately
40% of OAB patients either do not achieve an acceptable level of
a therapeutic benefit or remain completely refractory to
treatment with conservative measures and antimuscarinics
(Giarenis et al., 2013). Based on our observations that OAB
patients have a higher incidence of bacterial infection, as
demonstrated by enhanced culture techniques, it is plausible
that these patients have unidentified urinary infections. The
eradication of these subclinical infections, identified through
the enhanced culture method used in the current study, by
treatment with antibiotics might lead to simultaneous
improvements in OAB symptoms and should form the basis of
a future clinical trial.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6DATA AVAILABILITY STATEMENT
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